X hits on this document

189 views

0 shares

0 downloads

0 comments

57 / 57

We need adequately powered clinical trials to….

1. Determine what is the most simple, inexpensive, and rapid test of platelet function and/or metabolism genotyping that best predicts clinical outcomes of

antiplatelet therapy for specific patient subgroups?  AND STICK TO IT….results in trials discussed seem to vary by assay!

2. Determine if individual outcomes are affected when treatment is

changed in response to the testing results. i.e. what is our “threshold” or “cutoff” values

3. What the benefit of supplementary treatment with an agent having a different mechanism of action in patients with known hypo-response to a given antiplatelet agent?

4. With emerging agents, is any of this ultimately going to matter?

Adapted from H. Aboul-Enein, Benha Faculty of Medicine

HOW DO WE MOVE FORWARD?

Document info
Document views189
Page views189
Page last viewedMon Jan 16 19:49:14 UTC 2017
Pages57
Paragraphs810
Words3494

Comments